Core Viewpoint - Four Seasons Pharmaceutical (0460.HK) has seen a significant stock price increase, rising 7.53% to HKD 1.57, nearing its 3.5-year high of HKD 1.58, with a market capitalization exceeding HKD 14 billion. The stock has appreciated approximately 138% year-to-date, nearly doubling from its low of HKD 0.53 on April 7, 2023 [1] Group 1 - The company announced a framework agreement with Deep Origin Pharmaceutical Biotechnology (Beijing) Co., Ltd. to promote the application of artificial intelligence (AI) in the research and development of medical beauty products [1] - A joint AI R&D company will be established, led by Four Seasons Pharmaceutical, to explore AI-driven new medical beauty product development, marking a significant step in the company's strategic layout in the "AI + Medical Beauty" innovation sector [1] - The collaboration focuses on deep integration of "resources + technology" to create a "dry-wet closed-loop" R&D platform, enhancing the value of the company's medical beauty business through two main aspects: overcoming raw material bottlenecks and reducing costs while increasing efficiency [1] Group 2 - The AI R&D company will serve as the core of the company's ongoing efforts to deepen AI applications in medical beauty R&D, addressing unmet market needs and injecting momentum into the long-term development of the medical beauty business [1] - The initiative aims to enhance the company's core competitiveness and market value within the medical beauty industry through technological innovation and platform synergy [1]
港股异动丨四环医药涨超7%逼近逾3年半新高 股价较年内低点反弹近2倍 “AI+医美”战略布局进入实质性阶段